Evidence
Liver Int. 2023 Jun 29. doi: 10.1111/liv.15656. Online ahead of print.
ABSTRACT
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and poses a significant threat to patients with type 2 diabetes mellitus (T2DM) and metabolic dysregulation. Statins exert anti-inflammatory, antioxidative and antithrombotic effects that target mechanisms underlying NAFLD. However, the protective effects of the different doses, intensities and types of statins on the incidence of NAFLD-related decompensated liver cirrhosis (DLC) in patients with T2DM remain unclear.
METHODS: This study used the data of patients with T2DM who were non-HBV and non-HCV carriers from a national population database to examine the protective effects of statin use on DLC incidence through propensity score matching. The incidence rate (IR) and incidence rate ratios (IRRs) of DLC in patients with T2DM with or without statin use were calculated.
RESULTS: A higher cumulative dose and specific types of statins, namely rosuvastatin, pravastatin, atorvastatin, simvastatin and fluvastatin, reduced the risk of DLC in patients with T2DM. Statin use was associated with a significant reduction in the risk of DLC (HR: .65, 95% CI: .61-.70). The optimal daily intensity of statin use with the lowest risk of DLC was .88 defined daily dose (DDD).
CONCLUSIONS: The results revealed the protective effects of specific types of statins on DLC risk in patients with T2DM and indicated a dose-response relationship. Additional studies are warranted to understand the specific mechanisms of action of different types of statins and their effect on DLC risk in patients with T2DM.
PMID:37381761 | DOI:10.1111/liv.15656
Add to Google Keep
Estimated reading time: 5 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM
🌐 90 Days
VR Related Evidence Matrix
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Liver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients
- Oxidative Balance Score and New-Onset Type 2 Diabetes Mellitus in Korean Adults without Non-Alcoholic Fatty Liver Disease: Korean Genome and Epidemiology Study-Health Examinees (KoGES-HEXA) Cohort
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
- The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
- The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD
- Sex differences in mortality and liver-related events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) Among Diabetic Mellitus Patients in Saudi Arabia: Systematic Review and Meta-Analysis
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Treat Obesity to Treat Type 2 Diabetes Mellitus
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- A bibliometric analysis of macrophages associated with non-alcoholic fatty liver disease research from 2005 to 2023
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Serine protease inhibitor from the muscle larval Trichinella spiralis ameliorates non-alcoholic fatty liver disease in mice via anti-inflammatory properties and gut-liver crosstalk
- Shortness of breath due to portopulmonary hypertension and hepatopulmonary syndrome: diagnostic challenges and complex management approach in frail patients
- Occult liver disease: a multinational perspective
- Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling
- Costunolide attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Inflammatory liver diseases and susceptibility to sepsis
- Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
Evidence Blueprint
Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM
🌐 365 Days
VR Related Evidence Matrix
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Non-alcoholic fatty liver disease is associated with an increased risk of type 2 diabetes
- Synergistic effect of non-alcoholic fatty liver disease and history of gestational diabetes to increase risk of type 2 diabetes
- Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography
- Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer
- Liver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients
- Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease
- Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
- Comparison of aspartate aminotransferase platelet ratio index score and insulin resistance in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
- Oxidative Balance Score and New-Onset Type 2 Diabetes Mellitus in Korean Adults without Non-Alcoholic Fatty Liver Disease: Korean Genome and Epidemiology Study-Health Examinees (KoGES-HEXA) Cohort
- Prevalence and Prognostic Value of Non-Alcoholic Fatty Liver Disease in Patients Hospitalized With Decompensated Chronic Heart Failure
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD
- The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
- The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
- Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
- Risk of infections in non-alcoholic fatty liver disease: A nationwide population-based cohort study
- Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
- Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Sensitivity and specificity of three diabetes diagnostic criteria in people with non-alcoholic fatty liver disease (NAFLD) and otherwise healthy people: Analysis of NHANES III
- Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y
- The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
- Dietary inflammatory index (DII) is correlated with the incidence of non-alcoholic fatty liver disease (NAFLD): Fasa PERSIAN cohort study
- Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: a retrospective cohort study
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Gut mycobiome and metabolic diseases: The known, the unknown, and the future
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
- Statins as a Potential Treatment for Non-Alcoholic Fatty Liver Disease: Target Deconvolution using Protein-protein Interaction Network Analysis
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- An evaluation of the effects of mixed heavy metals on prediabetes and type 2 diabetes: epidemiological and toxicogenomic analysis
- An update on the effect of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease: A systematic review of clinical trials
- Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
- Impact of prior HBV, HAV, and HEV infection on non-alcoholic fatty liver disease
- Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals
- Diagnostic Performance of Greyscale Ultrasound in Detecting Fatty Liver Disease in a Type 2 Diabetes Population Using FibroScan as the Reference Standard
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
- Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
- Statins are associated with a decreased risk of severe liver disease in individuals with non-cirrhotic chronic liver disease
- Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials